Clinical CRO Merger: China's dMed Joins Forces with US-Based Clinipace
publication date: Apr 28, 2021
dMed Global, a Shanghai clinical CRO, merged with Clinipace, a North Carolina clinical CRO, to offer cross-border clinical contract research services. In 2016, dMed was founded by Dr. Lingshi Tan, who had been the first General Manager of Pfizer's China R&D Center. In 2019, dMed acquired US-based Target Health, a high-tech CRO with expertise in digital capabilities and regulatory affairs. dMed employs nearly 700 professional staff in more than 31 China cities and three US offices. Both CROs offer services to biotech, pharma and medical device companies. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.